Visitors and news

This guidance published today by WHO is intended to be used by programme managers following the decision to introduce human papillomavirus (HPV) virological testing as a screening assay in their national cervical cancer prevention and control programme. The guidance includes a step-by-step process to be followed after the decision has been made to specifically introduce and/or scale-up HPV virological testing for screening, which would be followed up with adequate management within the context of cervical cancer prevention.
View the publication.

In August 2020, the World Health Assembly passed a resolution calling for elimination of cervical cancer and adopting a strategy to make it happen. On November 17 (14:30 – 17:45 CET), World Health Organization will mark this historic announcement and officially launch the ambitious, inclusive global strategy to accelerate the elimination of cervical cancer. View the live session of the WHO Global Strategy to Accelerate the Elimination of Cervical Cancer.

Human papillomavirus (HPV) vaccination is safe and efficacious to prevent persistent HPV infection, precancerous anogenital lesions and cervical cancer. However, in countries where vaccination programmes are implemented outside of schools, such as France, reaching high HPV vaccination coverage of the target population is challenging. Like in other countries, the HPV vaccination decision of French parents is driven by the recommendations of their general practitioners (GPs). GPs are then key elements to target if we would like to improve uptake of the HPV vaccination in France. To provide a more comprehensive overview of French GPs’ cognitions and behaviour regarding HPV vaccination, Dr Villain and collaborators have used an innovative approach. They conducted a systematic review of all the available evidence in France using the a reasoned action approach (RAA) theory to (i) report GPs’ cognitions and beliefs, and (ii) examine the impacts of these cognitions on GPs’ behaviours. The methods used and the results are reported in the paper. View the article

Dr Catherine Sauvaget and colleagues from Japan published a study about the HPV vaccine effectiveness on the development of precancerous lesions (CIN2 and CIN3). Since June 2013, HPV vaccination is no more included in the National Immunization Programme and is not actively recommended by the Japanese Ministry of Health. We report in BMC Infectious Diseases Journal, a high effectiveness of the vaccine against CIN2-3 lesions.
View the article

Dr Partha Basu, Head of Screening Group, Early Detection & Prevention Section at the International Agency for Research on Cancer participated to this international webinar organized by the Indian Cancer Society to discuss cervical cancer prevention. Learn more about the Indian Cancer Society.

Continuation of the CanScreen5 Train the Trainers African course, with participants from 17 African countries. The CanScreen5 Train the Trainers course aims to contribute to the creation of a dynamic global network of master trainers capable of training health care providers on cancer screening program monitoring, evaluation and quality improvement and also to contribute data to the CanScreen5 project. Today, Dr Loubna Abousselham, Cancer Prevention and Control Unit, Non-Communicable Diseases Department, Ministry of Health, Morocco, addressed a key not lecture about the implementation of early detection of breast and cervical cancer national programmes: Moroccan experience. Learn more about the CanScreen5 platform.

Sander de Souza, medical resident in public health from Lyon 1 University, has recently joined the screening group at IARC as fellow. Sander will be involved in implementing an online education intervention regarding HPV vaccination and targeting French general practitioners (PAPRICA project) mainly in Lyon Metropole area.

This virtual conference organized by National Cancer Institute, National Institutes of Health (NCI/NIH) will offer a venue to discuss major public health needs, and to describe current research and development efforts in global cancer integrative oncology Dr Partha Basu, Head of Screening Group, Early Detection & Prevention Section at the International Agency for Research on Cancer will deliver a keynote address about the scopes and challenges of integrative oncology in cancer prevention, therapy and survivorship. View the virtual conference agenda and the session abstracts.

This webinar organized by the Royal Society of Medicine, UK is part of the London Global Cancer Week 2020 - a series coordinated with over 20 different events providing a comprehensive picture of the impact of the rising incidence of cancer in emerging countries. Join this global movement to address the disparities in cancer care in low and middle income countries, and learn how to address this through collaborative networks. Once again, this webinar will bring together healthcare professionals from around the world to awareness of topical issues globally faced in oncology. View the RSM Oncology Section webinar at London Global Cancer Week 2020 page and the flyer.

Continuation of the CanScreen5 Train the Trainers African course, with participants from 17 African countries. This course has been designed using a blended learning approach, i.e. an approach that uses a mix of e-learning and in-person activities. Today, Dr Suleeporn Sangrajrang deputy director, health system development, National Cancer Institute, Thailand, addressed a key not lecture about cancer screening experience from Thailand. Learn more about the CanScreen5 platform.